ABSTRACT

While conjugate vaccines against typhoid fever have recently been recommended by the World Health Organization for deployment, the lack of a vaccine against paratyphoid, multidrug resistance and chronic carriage all present challenges for the elimination of enteric fever. In the past decade, the development of in vitro and human challenge models has resulted in major advances in our understanding of enteric fever pathogenesis. In this review, we summarise these advances, outlining mechanisms of host restriction, intestinal invasion, interactions with innate immunity and chronic carriage, and discuss how this knowledge may progress future vaccines and antimicrobials.

Keywords: enteric fever; typhoid; Salmonella Typhi; Salmonella Paratyphi A; bacterial pathogenesis; enteric infection

INTRODUCTION

Typhoid and paratyphoid fever are caused by systemic infection with Salmonella enterica serovars Typhi and Paratyphi A, B or C, collectively referred to as enteric fever. Of the 14 million cases of enteric fever per year, 10.9 million are attributed to typhoid, and 3.4 million to paratyphoid (Stanaway et al. 2019). Transmitted through faecal contamination of food and water, enteric fever is chiefly endemic in South Asia and Africa. The highest burden is in children under 14 years of age. In 2017, enteric fever was estimated to cause 9.8 million disability-adjusted life years and 136 000 deaths (Stanaway et al. 2019).

The species S. enterica is classified into over 2000 serovars based on their lipopolysaccharide (LPS) and flagellar antigens (World Health Organization 2007). Many of the virulence factors required for Salmonella infection are encoded by clusters of genes known as Salmonella pathogenicity islands (SPIs), which vary between serovars (Marcus et al. 2000). Enteric fever is most commonly caused by serovars S. Typhi and S. Paratyphi A. Salmonella Paratyphi C can also cause enteric fever, as can strains of S. Paratyphi B unable to ferment the organic compound d-tartrate (Pinna, Weill and Peters 2016). Human gastroenteritis and invasive non-typhoidal Salmonella disease are most commonly caused by serovars S. Typhimurium and S. Enteritidis (Gal-Mor, Boyle and Grassl 2014).
Unlike S. Typhi, S. Typhimurium is not human restricted, and is able to disseminate systemically in orally challenged mice. It has therefore frequently been used as a model of enteric fever (Higgins, Simon and Tennant 2016). In 2010, there were few clues as to why S. Typhi is restricted to infecting humans. While a high number of pseudogenes were known to be characteristic of host-restricted Salmonella genomes (McClelland et al. 2004), and the capsular Vi polysaccharide produced by S. Typhi to be immunosuppressive (Wilson et al. 2008), mechanisms by which host adaptation modifies host-pathogen interactions have only recently been coming to light. These mechanisms will be discussed in more detail in later sections and are summarised in Fig. 1 and Table 1. Furthermore, as each of the typhoidal serovars underwent genome degradation independently (Didelot et al. 2007; Pinna, Weill and Peters 2016; Nair et al. 2020), clues as to how S. Paratyphi A is able to cause systemic disease are only now emerging (Hiyoshi et al. 2018).

The past decade has seen huge advances in our understanding of the pathogenesis of enteric fever. Particularly important have been development of in vitro typhoid models and human experimental infection challenge studies, overcoming the limitation of using the genetically distinct S. Typhimurium as a model pathogen. These research efforts have been paralleled by urgent vaccine development to control the disease, culminating in recommendations by the World Health Organization to deploy new typhoid conjugate vaccines in high-burden regions of the world. In this review, we discuss advances in the underpinning biology, including putative mechanisms of host restriction, the means by which typhoidal serovars manipulate innate immunity to disseminate systemically, chronic carriage and the implications for human health.

**GASTROINTESTINAL INVASION**

**Anatomical barriers to infection**

Upon ingestion of contaminated food or water by a human host, S. Typhi faces hostile conditions in the stomach and small intestinal lumen before invading the terminal ileum (Dougan and Baker 2014). The very first barrier to infection is gastric acid. While a high proportion of bacteria are likely killed in the stomach, for those that do survive, the exposure to acid may signal an arrival in a new host, acting as a stimulus for S. Typhi replication (Ahirwar et al. 2014).

The human gut microbiota, consisting of commensal bacteria colonising the gut lumen and mucosa, is thought to play a key role in defence against pathogen invasion. Unlike S. Typhimurium, which is able to metabolise butyrate produced by the microbiota and colonise the intestinal lumen, S. Typhi and S. Paratyphi A lack the required operon (Bronner et al. 2018). Despite this, stools rich in transcripts from methane-producing archaea have been associated with a marginally lower risk of developing typhoid after human challenge, suggesting that the microbiome may play a role in enteric fever susceptibility (Zhang et al. 2018).

Salmonella Typhi must traverse the bactericidal layer of mucus coating the intestinal wall. Mucus predominantly consists of highly glycosylated proteins called mucins (Johansson and Hansson 2016). This layer changes dynamically in response to infection to strengthen the barrier; S. Typhi infection induces upregulation of secreted gel-forming mucins MUC2 and MUC5B in an intestinal co-culture model and ex vivo intestinal biopsies, respectively (Nickerson et al. 2018; Salerno-Goncalves et al. 2018). In addition to acting as a barrier, the mucus is enriched with antimicrobial peptides, including α-defensins HD5 and HD6, and human β-defensins 1 and 2. In intestinal biopsies from human volunteers administered S. Typhi vaccine strain Ty21a, HD5 messenger RNA (mRNA) was downregulated, potentially representing a means of immune evasion (Simuyandi and Kapulu 2016). However, β-defensins, shown to be bactericidal against S. Typhi in vitro, and protective in mice infected intraperitoneally with S. Typhi (Maiti et al. 2014), were unchanged. The bactericidal activity of β-defensins against S. Typhi suggests that antimicrobial peptides could have potential as a therapy for antibiotic-resistant enteric fever. In a Phase 3 trial, antimicrobial peptide surotomycin has been demonstrated as non-inferior to vancomycin for Clostridium difficile treatment, indicating that such an approach could be effective against gastrointestinal infections (Daley et al. 2017). Such a treatment could hypothetically be used as a prophylactic in outbreak settings or reduce transmission through stool shedding.

In addition to antimicrobial peptides, secretory immunoglobulin A (IgA) is thought to protect the intestinal epithelium by blocking bacterial uptake and inhibiting flagellar motility (Betz et al. 2018). The role of secretory IgA in protection against enteric fever is not yet well characterised. In human challenge participants, a drop in peripheral B cells and a rise in B cell α4β7 expression are observed during acute disease, suggestive of gut homing (Toapanta et al. 2016), while oral vaccination with attenuated S. Typhi strain Ty21a significantly increases S. Typhi-specific stool IgA (Arya and Agarwal 2014). Serum Vi IgA is associated with protection in Vi-polysaccharide-vaccinated human challenge participants (Dahora et al. 2019), but no relationship has been elucidated between gut IgA and protection against enteric fever. Interestingly, mice lacking the polymeric immunoglobulin receptor required for IgA transport to the intestinal lumen are significantly more resistant to S. Typhimurium infection (Betz et al. 2018), although the potential reasons for this are numerous—possibly due to changes in the microbiome, compensation by serum antibodies or IgG, or reduced M-cell-mediated uptake—and may act in combination.

Underneath the mucus layer, the glycocalyx, composed of glycolipids and glycoproteins extending from the plasma membrane of intestinal epithelial cells, serves as an additional protective barrier. Salmonella Typhimurium uses two glycosyl hydrolases, nanH and malS, to degrade the glycocalyx, without which it is cannot efficiently invade (Arabyan et al. 2016). While the typhoidal serovars do not possess nanH, malS is present in S. Typhi, S. Paratyphi A and S. Paratyphi B with over 97% sequence identity (UniProt 2019).

**Invasion of the intestinal epithelium**

At the surface of the intestinal epithelium, S. Typhi attaches to epithelial cells using fimbriae (Berrocal et al. 2015) (Fig. 2), extracellular protein structures that mediate bacterial adhesion to epithelial cells. Fimbriae may play a role in host specificity: recombinant Escherichia coli expressing S. Typhi fimH is only able to strongly bind human epithelial cells, whereas E. coli expressing fimH from porcine-, bovine- and avian-adapted Salmonella serovars specifically binds cells from their respective hosts (Yue et al. 2017). Escherichia coli expressing S. Typhimurium fimH weakly binds cells from a variety of hosts at equal affinity, possibly reflecting its niche as a non-invasive broad-specificity serovar. While fimH is shared with high homology between Salmonella serovars, including S. Paratyphi A, B and C, single-nucleotide polymorphisms in this gene are sufficient to change host-specific adhesion (Yue et al. 2017; UniProt 2019).
Figure 1. Hypothesised mechanisms of host restriction. (A) *Salmonella Typhi* fimbriae are specific for adhesion to human epithelial cells, while *S. Typhimurium* fimbriae can adhere to cells from a variety of hosts. (B) *Salmonella Typhimurium* produces bacterial effector GtgE that cleaves Rab32, preventing killing in mouse macrophages. *Salmonella Typhi* lacks GtgE and is therefore killed in mouse macrophages. (C) *Salmonella Typhi* is more susceptible to iron starvation than *S. Typhimurium* in vitro and in mice, and therefore is only able to infect iron-overloaded mice. (D) The typhoid toxin is secreted by intracellular bacteria into the *Salmonella*-containing vacuole and transported to the extracellular space. Here, it binds to target cell receptors (PODXL on epithelial cells, CD45 on macrophages and T and B cells; Galán 2016). The toxin preferentially binds to glycans terminated by Neu5Ac, characteristic of human cells. In the nucleus of target cells, the DNase activity of the toxin causes DNA damage and cell cycle arrest.

Table 1. Summary of the evidence as to why *S. Typhi* is invasive in humans but not mice, and why *S. Typhimurium* is invasive in mice but not humans.

|                      | Mice                  | Humans                                                                 |
|----------------------|-----------------------|------------------------------------------------------------------------|
| *S. Typhi*           | Non-invasive          | Invasive                                                              |
|                      | *S. Typhi* lacks gtgE to break down Rab32 in mice | The action of the typhoid toxin is human specific                     |
|                      | *S. Typhi* is susceptible to iron starvation in mice | *S. Typhi* FimH specifically binds human cells                           |
| *S. Typhimurium*     | Invasive              | Non-invasive                                                          |
|                      | *S. Typhimurium* is less susceptible to iron starvation | S. *Typhimurium* FimH only weakly binds human cells                     |
|                      | *S. Typhimurium* produces gtgE to break down Rab32 | Induces an innate immune response at the intestinal epithelium and inflammatory diarrhoea |

In the high osmolarity environment of the intestinal lumen, the bacterial sensor kinase EnvZ phosphorylates the downstream regulator OmpR (Nuccio, Rüssmann and Bäumler 2010). This in turn suppresses *S. Typhi* expression of TviA, a key regulatory protein encoded within the viaB operon of the serovar-specific SPI-7 locus (Nuccio, Rüssmann and Bäumler et al. 2010) (Fig. 3). Low levels of TviA result in expression of type III secretion system 1 (T3SS1), a needle-like protein complex used to inject Salmonella effectors into the host cytosol, and flagellin, thus allowing invasion of the intestinal epithelium (Nuccio, Rüssmann and Bäumler 2010). High osmolarity also induces *S. Typhi* to express SPI-9, enhancing adherence to epithelial cells (Velásquez et al. 2016). It has long been thought that *S. Typhi* targets specialised antigen-sampling epithelial cells known as M cells for invasion (Dougan and Baker 2014). However, it lacks the long polar fimbriae used by *S. Typhimurium* to recognise M
Figure 2. Invasion of the intestinal epithelium by S. Typhi. Salmonella Typhi invasion is impeded by mucus and the glycocalyx acting as physical barriers, as well as the action of defensins, cathelicidins and IgA in the intestinal mucosa. Those bacteria that successfully adhere to the epithelium using fimbriae cross by T3SS-1- or STIV-mediated invasion of intestinal epithelial cells. Bacteria in the lamina propria and subepithelial dome (SED) are then phagocytosed and systemically disseminated to the liver and spleen via the blood and lymph.

Figure 3. Genetic regulation in response to changes in osmolarity. In the high osmolarity intestinal lumen, EnvZ auto-phosphorylation activity is high, ultimately resulting in the phosphorylation of OmpR and suppression of the viaB locus. Thus, Vi capsule biosynthesis is suppressed, while T3SS-1 and flagellin expression can take place. In the lower osmolarity environment inside cells, EnvZ undergoes a conformational change that reduces auto-phosphorylation. The viaB locus is hence expressed, resulting in synthesis of TviA and the Vi capsule. Regulatory protein TviA then goes on to suppress T3SS1 and flagellin expression. Under high osmolarity conditions, SPI-9 is also transcribed by a mechanism dependent on rpoS.

cells, and in fact appears to preferentially invade enterocytes in a co-culture model and in ex vivo biopsies (Gonzales, Wilde and Roland 2017; Nickerson et al. 2018). Nonetheless, this question is difficult to resolve fully due to the high numbers of enterocytes in the intestinal epithelium relative to M cells, and the inability to follow gastrointestinal infection in vivo in humans.

The chief mechanism of Salmonella epithelial invasion is mediated by T3SS-1, a molecular needle encoded by the relatively conserved SPI-1 locus (Sabbagh et al. 2010). Salmonella Typhimurium injects effector proteins SipA, SipC, SopE and SopE2 into the host cytosol. The effectors activate Rho-family GTPases, small signalling proteins that control cytoskeleton
dynamics (Hodge and Ridley 2016). This results in cytoskeletal rearrangement so as to engulf S. Typhimurium. Surprisingly, the effector protein SopE2 inhibits epithelial cell invasion (Valenzuela et al. 2015). In S. Typhimurium the bacterial ubiquitin ligase SopA counteracts the inhibitory effect of SopE2, allowing invasion to take place but also inducing interleukin-8 (IL-8) secretion (Valenzuela et al. 2015). In S. Typhi both SopA and SopE2 are pseudogenes, allowing it to invade cells while avoiding production of IL-8. Salmonella Paratyphi A, however, possesses SopE2 but not SopA (Johnson, Mylona and Frankel 2018). Like S. Typhimurium, S. Typhi infection induces the enterocyte cytoskeleton to protrude at sites of invasion (Nickerson et al. 2018). Reacting to invasion by S. Typhi, enterocytes downregulate genes involved in cytoskeleton remodelling (Nickerson et al. 2018). This may represent a host response to prevent further infection, as pharmacological inhibition of actin or microtubule assembly almost entirely blocks S. Typhi uptake.

To avoid excessive Rho-family GTPase stimulation, which would lead to the activation of NF-κB and inflammatory gene expression (Winter et al. 2014), S. Typhimurium effector SptP reverses these changes to the cytoskeleton, while the effector AvrA blocks nuclear translocation of NF-κB subunit p65 (Collier-Hyams et al. 2002). In S. Typhi, however, a different strategy is required, as the gene encoding AvrA is absent and its translated SptP protein is too unstable to be secreted. Rather, sensing the drop in osmolarity as it enters the cell, S. Typhi upregulates TviA, resulting in concomitant downregulation of T3SS-1 (Nuccio, Rüssmann and Bäumler 2010). By doing so, excessive Rho-family GTPase stimulation is avoided, preventing the associated induction of NF-κB signalling (Winter et al. 2014). It is unclear which of these strategies is more successful: whereas S. Typhi induces greater NF-κB responses than S. Typhimurium in infected Henle-407 cells, in ex vivo infected intestinal biopsies the opposite appears to be true (Hannemann and Galán 2017; Nickerson et al. 2018). Unlike S. Typhimurium, S. Typhi does not induce activation of STAT3, a transcription factor that upregulates IL-10 in response to S. Typhimurium infection (Hannemann and Galán 2017; Jaslow et al. 2018). This is likely due to the lack of SopE2 (Ruan et al. 2017) and Sara (Jaslow et al. 2018) in S. Typhi. Although T3SS-1-dependent invasion is well characterised, S. Typhi is also able to invade epithelial cells via bacterio outer membrane protein STIV, binding the receptor tyrosine kinase Met to induce uptake (Chowdhury et al. 2019). Both the typhoidal and non-typhoidal Salmonella serovars possess STIV (UniProt 2019).

Having passed through the epithelium, S. Typhimurium flagellin activates toll-like receptor (TLR)-5 at the basolateral surface, giving rise to neutrophil recruitment and inflammatory diarrhoea (Keestra-Gounder, Tsolis and Bäumler 2015). In S. Typhi, however, the additional role of TviA in mediating downregulation of TLR-5 recognition, as well as activating biosynthesis of the protective Vi polysaccharide capsule. Infection of human colonic explants with wild-type S. Typhi elicits a RANTES expression relative to a ΔtviAS. Typhi strain (Raffatellu et al. 2005). It may be this upregulation of the Vi capsule as the bacterium crosses the intestinal barrier that renders it immediately susceptible to immunoglobulin binding by Vi-based typhoid vaccines.

Although S. Typhi is able to pass through the epithelium without causing inflammatory diarrhoea, there is evidence to suggest a host cytokine response occurs at this point. In a coculture model of the intestinal epithelium, IL1β, IL17A, TNF-α, IL6, CCL3 and IL8 were released in response to S. Typhi infection (Salerno-Goncalves et al. 2019). Although secretion of TNF-α, IL6 and CCL3 was reduced in the absence of macrophages, of these three cytokines only TNF-α was directly produced by macrophages in response to stimulation, suggesting that macrophages may modulate cytokine secretion by other cells in the intestinal mucosa. Salmonella Paratyphi B induced greater secretion of IL6 and TNF-α than S. Paratyphi A or S. Typhi, while S. Paratyphi A induced greater secretion of CCL3 (Salerno-Goncalves et al. 2019). Despite possessing the via8 locus, S. Typhi still stimulated IL8 secretion from the fibroblasts, endothelial and epithelial cells in the model, as did S. Paratyphi A and B (Salerno-Goncalves et al. 2018, 2019). This may indicate that IL8 release is dampened down but still significant, or that the Vi capsule was poorly expressed under these culture conditions. Likewise, there was a trend towards apical IL8 secretion by intestinal biopsies in response to S. Typhi, as well as significant apical secretion of IL10, IL2 and IL4 (Nickerson et al. 2018). However, there was no significant cytokine release at the basolateral side, which could account for the lack of neutrophil infiltration in typhoid fever. Dose-dependent induction of plasma cytokines scCD40L, fractalkine, GROα, IL1RA, EGF and VEGF is observed in typhoid challenge participants within 12 h of challenge, the period in which intestinal invasion is expected to take place; however, the origin of this signal is as yet unconfirmed (Blohmke et al. 2016).

This stage of infection likely represents the point at which antibodies induced by mucosal vaccines target invading S. Typhi, and there is increasing evidence that parenteral vaccines can also induce protective mucosal responses (Clements and Freytag 2016). Subcutaneous vaccination with STIV has been shown to protect iron-overloaded mice from death following S. Typhi and S. Paratyphi A challenge, and is therefore an attractive target for a bivalent vaccine. The role of T3SS-1 effector proteins in invasion also renders them potential targets: vaccination with SipD, for example, which controls assembly of the T3SS and is shared by S. Typhi, S. Paratyphi A and S. Typhimurium, is capable of protecting orally vaccinated mice against S. Typhimurium challenge (Fasciano et al. 2019). Likewise, subunit vaccines composed of SipB/SipD or SseB/SseC constructs, effectors shared between serovars, have also proved effective in protecting mice against S. Typhimurium challenge (Fasciano et al. 2019).

In summary, to invade the intestinal epithelium S. Typhi must first survive gastric acid exposure, evade antimicrobial peptides in the mucus and break down the glycocalyx. Upon reaching the epithelium, S. Typhi can then use its fimbriae to attach to enterocytes, and induce uptake using T3SS-1 or STIV. To avoid immune activation via Rho-family GTPase stimulation or TLR-5, the TviA locus allows S. Typhi to respond to changes in osmolarity by downregulating T3SS-1 and flagellin, and upregulating the immunomodulatory Vi capsule.

**INTERACTION WITH INNATE HOST DEFENCES**

**Dissemination via mononuclear phagocytes**

Although S. Typhi DNA has been detected in the blood of human challenge participants in the first 24 h following challenge (Darton et al. 2017), there is currently no direct evidence to show how S. Typhi disseminates systemically to the spleen and liver in humans. Mouse models using S. Typhimurium suggest dissemination is mediated by migration of infected mononuclear phagocytes from the intestine into the blood or lymph (Vazquez-Torres et al. 1999). Pseudogenisation of bacterial effector SseI, which has occurred in both S. Typhi and strains of the invasive
S. Typhimurium sequence type ST313, enhances systemic dissemination of S. Typhimurium in orally challenged mice due to increased uptake by CD11b⁺ migratory dendritic cells (Carden et al. 2017).

In order to achieve dissemination within mononuclear phagocytes, S. Typhi must evade detection and killing by these cells. Although S. Typhi can be phagocytosed, uptake of S. Typhi and S. Paratyphi A is reduced in the absence of functional flagella (Elhadad et al. 2015; Schreiber et al. 2015) and fimbriae (Berrocal et al. 2015), suggesting that phagocytosis can also be actively invaded. During entry to these cells the S. Typhi Vi capsule has a variety of immunomodulatory effects. Vi masks LPS from recognition by TLR-4 on the cell surface, preventing subsequent release of inflammatory cytokines TNF-α, IL6 or IL8 (Wilson et al. 2008), and reduces phagocytosis-mediated by BPI, an antimicrobial protein that binds LPS (Balakrishnan, Schnare and Chakravorty 2016). Despite the absence of Vi, the percentage of IL8⁺ macrophages following stimulation with S. Paratyphi A and B is no greater than after stimulation with S. Typhi, suggesting that these serovars may possess alternative mechanisms to suppress IL8 secretion (Salerno-Goncalves et al. 2019). For example, although S. Paratyphi A LPS is exposed and capable of binding TLR-4, it does not activate it, acting as a competitive TLR-4 inhibitor in the presence of S. Typhimurium LPS (Chessa et al. 2014).

Having formed a vacuole within the cells, in order to survive S. Typhi needs to avoid host-derived reactive oxygen and nitrogen species. In the absence of TLR-4-mediated NF-κB activation the transcription of inducible nitric oxide synthase is reduced, limiting synthesis of bactericidal nitric oxide (Wilson et al. 2008). The acidic environment of the Salmonella containing vacuole induces expression of SPI-2, allowing S. Typhimurium to prevent NADPH oxidase assembly on the phagosomal membrane and evade killing (Gallois et al. 2001; Liew et al. 2019). While SPI-2 deletion does reduce the virulence of S. Paratyphi A when injected into the peritoneum of mice, ability to colonise the liver and spleen is retained (Yin et al. 2020). In S. Typhi, knock out of SPI-2 has no effect on survival within human macrophages (Forest et al. 2010). The redundancy could in part be due to deterioration of epithelial invasion regulator marT into a pseudogene in S. Typhi, creating a new open reading frame that appears to encode a novel H2O2-protective protein (Ortega et al. 2016). Furthermore, a eukaryote-like serine/threonine kinase unique to S. Typhi is induced in response to H2O2, promoting survival within macrophages and contributing to virulence in infected mice (Theeya et al. 2015). As inhibitors of eukaryotic serine/threonine kinases are already approved as cancer treatments, the eukaryote-like serine/threonine kinase unique to S. Typhi may be an attractive therapeutic target, rendering the bacteria more susceptible to killing by H2O2 (Kanniyan and Mahadeva 2017). The suf operon, involved in producing Iron-Sulphur clusters under oxidative stress, also appears to contribute to S. Typhi survival within macrophages (Wang et al. 2015). Within monocyte-derived dendritic cells, S. Typhi switches from carbohydrate to lipid consumption (Xu et al. 2019). The significance of this is not yet understood, although for S. Typhimurium lipid metabolism is necessary for replication within pro-inflammatory macrophages (Reens, Nagy and Detweiler 2020).

Within macrophages, S. Typhi must also avoid killing mediated by host protein Rab32 (Spano and Galán 2012). Although the mechanism of killing has not yet been elucidated, Rab32 is involved in the delivery of cargo to lysosome-related organelles, and therefore may allow delivery of antimicrobial proteins to the Salmonella containing vacuole (Spano and Galán 2012). While S. Typhimurium produces the protease giiE, allowing it to break down Rab32 and therefore survive in mouse macrophages, S. Typhi does not, resulting in rapid killing. In human macrophages, however, S. Typhi is instead thought to counter this pathway through a mechanism dependent on its SPI-1-encoded T3SS1 (Baldassarre et al. 2019).

Rather than being killed, internalised Salmonella can induce macrophage death; however, it is as yet unknown whether this acts to benefit the bacteria or the host. For S. Typhimurium, bacterial effector protein SipB activates caspase-1, resulting in a rapid and inflammatory cell death known as pyroptosis (Chen et al. 2015). SipB knockout reduces the virulence of S. Typhimurium in mice, and is also present in the typhoidal Salmonella serovars (Chen et al. 2015; UniProt 2019). In addition to direct activation by bacterial effectors, recognition of S. Typhimurium flagellin by sensor protein NAIP activates the NLRC4 inflammasome, a multiprotein complex that induces caspase-1 activation (Kortmann, Brubaker and Monack 2015; Winter et al. 2015; Brewer, Brubaker and Monack 2019). This suggests that S. Typhimurium-induced cell death could in fact represent a protective host response. The temporal association between pyroptosis and S. Typhimurium clearance has led to the suggestion that bacterial release from dying macrophages leaves S. Typhimurium vulnerable to uptake and killing by neutrophils (Miao et al. 2010). This has been confirmed by mouse experiments finding that caspase-1 knockout reduces bacterial clearance by neutrophils and increases susceptibility to S. Typhimurium (Broz et al. 2012). Although S. Typhi flagellin is a particularly potent NLRC4 activator (Yang et al. 2014), the TviA-dependent downregulation of flagellin appears to reduce NLRC4 activation and pyroptosis, potentially acting as a means of immune evasion (Winter et al. 2015). In contrast, typhoidal serovar S. Paratyphi A induces a high level of macrophage killing (Salerno-Goncalves et al. 2019).

During acute disease the level of iron-regulating hormone hepcidin is significantly raised in the serum, resulting in the sequestration of iron within macrophages (Darton et al. 2015). Iron starvation is an important mechanism of host defence, as illustrated by the susceptibility of iron-overloaded mice to S. Typhi infection (Das et al. 2019). This raises the possibility of sequestering iron from S. Typhi as a feasible strategy for treatment. While small molecule iron chelators such as desferrioxamine can be utilised by S. Typhi and therefore enhance growth, iron chelating polymers too large to be accessible to bacteria are capable of suppressing Staphylococcus aureus wound infections in mice (Parquet et al. 2018). While diversion of iron to macrophages in acute disease might restrict the growth of free bacteria, it could be advantageous to bacteria residing intracellularly. As well as being required for bacterial growth, iron activates S. Typhi ferric uptake regulator (Fur), repressing sRNAs RfrA and RfrB, and enhancing H2O2 resistance and intracellular survival through an unknown mechanism (Leclerc, Dozois and Daigle 2013). It has more recently been found that in the case of S. Typhimurium infection in Raw264.7 cells, hepcidin increases iron in the cytosol but decreases it in the Salmonella-containing vacuole (Lim, Suh Kim and Jeong 2018). Rather than starving S. Typhimurium, the lack of iron impairs production of bactericidal reactive oxygen species and results in a higher bacterial load in mice.

To summarise, following invasion S. Typhi is thought to be taken up by mononuclear phagocytes, through which it disseminates systemically in a primary bacteremia. Evasion of killing by upregulating H2O2-protective proteins and the Vi capsule,
and shielding LPS from TLR-4 to prevent iNOS transcription are important to allow S. Typhi to survive host defences. By down-regulating flagellin expression, S. Typhi is able to prevent its host cell undergoing pyroptosis, averting the resultant inflammation and uptake by neutrophils.

**Evading complement-dependent neutrophil activation**

The considerable efficacy of the T cell-independent Vi polysaccharide vaccine (Milligan et al. 2018) and the association between baseline LPS antibody and resistance to S. Paratyphi A in human challenge (Dobinson et al. 2017) suggests that at some stages during the course of infection, these typhoidal *Salmonella* bacteria must be extracellular, and therefore vulnerable to opsonisation. However, S. Typhi appears to have evolved several mechanisms to evade complement-dependent opsonisation and killing (Fig. 4): shielding by the Vi capsule, LPS modification and breakdown of complement components by PgtE. The lack of free hydroxyl groups in the Vi capsule prevents C3b from binding the bacterial surface (Wilson et al. 2011). In the absence of Vi-specific antibodies, the Vi capsule also reduces IgG, C3 and membrane attack complex binding (Hart et al. 2016). This protection is enhanced by a nonsense mutation in the *fepE* gene, preventing synthesis of very long O-antigen chains that would expose hydroxyl groups to C3b at the capsule surface (Crawford et al. 2013). In addition, S. Typhi shares an operon with *S. Typhimurium* that glucosylates the O-antigen on LPS to reduce C3 binding (Riva, Korhonen and Meri 2015). Conserved surface protease PgtE is present in both typhoidal and non-typhoidal serovars, and cleaves C3b, C4b and B (Kinzet et al. 2017; UniProt 2019). Therapeutically, it is possible that *Salmonella* could be rendered more susceptible to complement by inhibition of the complement-cleaving protease PgtE. In silico docking of FDA-approved protease inhibitors suggested that the antiretroviral drug indinavir bound PgtE with the highest affinity (Samykannu et al. 2018). However, this finding has not yet been validated experimentally. While S. Paratyphi A lacks the Vi capsule and produces functional *fepE*, the O-antigen of S. Paratyphi A differs due to the pseudogenisation of *rfbE*, giving it a branching paratose residue that prevents IgM-mediated activation of the classical complement pathway (Hiyoshi et al. 2018).

Despite correlating with disease attenuation, serum bactericidal antibody has not been found to associate with protection in the human challenge model to date (Juel et al. 2018). This raises the possibility that the direct role of complement in S. Typhi lysis is secondary to its role in attracting and activating phagocytes. Inhibition of complement deposition by factors such as the Vi capsule reduces generation of chemoattractant C5a, impairing neutrophil recruitment (Wangdi et al. 2014). However, in the presence of vaccination-induced antibodies against the Vi capsule, neutrophil phagocytosis of Vi-coated beads is increased, particularly in participants who remained healthy following subsequent S. Typhi challenge (Celina et al. 2021). Therefore, vaccination may act to overcome this method of evasion. Although peripheral blood neutrophil counts drop in acute disease, the peripheral blood transcriptome is dominated by clusters associated with neutrophils, suggesting a significant involvement in the immune/inflammatory response (Waddington et al. 2014; Blohmke et al. 2016). Calprotectin, a chelating protein complex that constitutes 40% of neutrophil cytosol, is raised in both the plasma and faeces of patients with typhoid fever, and is able to inhibit the growth of S. Typhi in vitro (De Jong et al. 2015). As in macrophages, neutrophil phagocytosis of S. Typhi or S. Paratyphi A fails to stimulate a bactericidal oxidative burst by NADPH oxidase (Hiyoshi et al. 2018), although it is not currently clear whether this is sufficient to suppress killing by neutrophils.

Overall, it appears that S. Typhi and S. Paratyphi A have undergone convergent evolution in order to evade complement binding, preventing chemo-attraction of neutrophils and therefore oxidative killing. The analogous role of S. Paratyphi LPS to the Vi capsule in immune evasion supports the pursuit of this antigen as an S. Paratyphi A vaccine target. While S. Paratyphi C also produces the protective Vi capsule, the mechanism by which typhoidal strains of S. Paratyphi B evade complement remains elusive.

**Natural killer cell stimulation**

While the role of natural killer (NK) cells is well established in viral and cancer immunity, a contribution to bacterial immunity has come to light more recently. In mice infected with *S. Typhimurium*, IL18-mediated recruitment of NK cells to the gut did not affect bacterial load, but did increase intestinal inflammation (Müller et al. 2016). Although gastrointestinal inflammation is not a hallmark of human enteric fever as it is in mice, the percentage of NK cells producing granzyme A does rise (De
Conclusions

Typhoidal Salmonella serovars are characterised by human restriction, and an ability to evade immune detection and disseminate systemically. Binding specificity of the typhoid toxin and fimbriae to human cells may explain how S. Typhi is able to cause disease in humans, while iron restriction or detection by Rab32 may explain why S. Typhi is less adept at infecting non-human hosts. These insights into host restriction are contributing to the development of relevant animal models, which will accelerate preclinical development of vaccines and novel antimicrobials. Following invasion of the intestinal epithelium, while S. Typhi is able to evade detection by TLR4, the classical complement pathway and oxidative killing through production of the Vi capsule, adaptations in the LPS structure of S. Typhimurium results in development of a long-term asymptomatic infection in the liver following murine challenge (Del Bel Belluz et al. 2016).

As chronic carriers may act as a reservoir for infection, and therefore provide a barrier in the elimination of enteric fever, innovative strategies will be necessary to identify and treat carriers. At present, carriers are identified on the basis of Vi seropositivity, which has a low positive predictive value and will not be discriminatory in a vaccinated population, or bacterial shedding, which is intermittent (Näström et al. 2018). The presence of a unique plasma metabolome signature in carriers presents a potential alternative avenue of diagnostics (Näström et al. 2018). As S. Typhi biofilms are generally antibiotic resistant, carriers are currently treated by surgical removal of the gallbladder. Treatment of carriers with biofilm modulators, currently under development to treat hospital-acquired infections, might represent a less invasive alternative (Vila, Moreno-Morales and Ballesté-Delpierre 2020). As S. Typhi biofilm formation appears to be dependent on quorum sensing, the use of acyl-homoserine lactonases to disrupt these signals may also hold potential. Finally, if the typhoid toxin emerges as a major player in chronic disease, monoclonal antitoxins could be an attractive treatment.
fever cases in future. As such, development of a bivalent vaccine would be hugely beneficial to public health in Asia, where the two infections are co-endemic. This review also highlights several virulence factors shared with S. Typhimurium, potential targets of bi- or trivalent vaccines against invasive Salmonella disease in Africa. Furthermore, as extensively drug-resistant infections rise, novel therapeutic strategies will be needed to treat infections. The pathogenesis of S. Paratyphi B- and C-mediated enteric fever remains a mystery, but currently presents a less pressing global health concern. Despite a chiefly unicellular lifestyle, typhoidal Salmonella is able to form a multicellular community on the surface of gallstones and persist long term in the host. However, it is still unclear whether chronic infection has more far-reaching effects on host immunity than inducing gallbladder inflammation, or which bacterial virulence factors are key for colonisation. Innovative methods in diagnosing and treating chronic carriers will be key in the elimination of enteric fever.

While it has long been known that S. Typhi infection induces incomplete immunity, the past decade has revealed a myriad of ways by which S. Typhi evades the human immune response. With the availability of new vaccine programmes to control the disease, there will be a substantial impact on human health, but understanding of the biology of immune evasion will be essential to ensure eventual elimination of enteric fever from the world.

**FUNDING**

This work was supported by the NIHR Oxford Biomedical Research Centre.

**Conflict of Interest.** AJP is Chair of the UK Department of Health and Social Care’s (DHSC) Joint Committee on Vaccination and Immunisation (JCVI) and is a member of the WHO’s Strategic Advisory Group of Experts. CJB is currently employed by GlaxoSmithKline.

**REFERENCES**

Adcox HE, Vasicsek EM, Dwivedi V et al. Salmonella extracellular matrix components influence biofilm formation and gallbladder colonization. *Infect Immun* 2016;84:3243–51.

Ahirwar SK, Prapat CB, Patel SK et al. Acid exposure induces multiplication of *Salmonella enterica* serovar Typhi. *J Clin Microbiol* 2014;52:4330–3.

Arabyan N, Park D, Foutouhi S et al. Salmonella degrades the host glycocalyx leading to altered infection and glycan remodeling. *Sci Rep* 2016;6:1–11.

Arya SC, Agarwal N. Evaluation of immune responses to an oral typhoid vaccine, Ty21a, in children from 2 to 5 years of age in Bangladesh. *Vaccine* 2014;32:1055–60.

Balakrishnan A, Schnare M, Chakravortty D. Of men not mice: bactericidal/penetrability-increasing protein expressed in human macrophages acts as a phagocytic receptor and modulates entry and replication of Gram-negative bacteria. *Front Immunol* 2016;7:455.

Baldassarre M, Solano-Collado V, Balci A et al. The Rab32/BLOC-3-dependent pathway mediates host defense against different pathogens in human macrophages. *Sci Adv* 2014;7:1–9.

Berrocal L, Fuentes JA, Trombert AN et al. stg fimbrial operon from *S. Typhi* STH2370 contributes to association and cell disruption of epithelial and macrophage-like cells. *Biol Res* 2015;48:34.

Betz KJ, Maier EA, Amarachinth S et al. Enhanced survival following oral and systemic *Salmonella enterica* serovar Typhimurium infection in polymeric immunoglobulin receptor knockout mice. *PLoS One* 2018;13:e0198434.

Blohmke CJ, Darton TC, Jones C et al. Interferon-driven alterations of the host’s amino acid metabolism in the pathogenesis of typhoid fever. *J Exp Med* 2016;213:1061–77.

Blohmke CJ, Hill J, Darton TC et al. Induction of cell cycle and NK cell responses by live-attenuated oral vaccines against typhoid fever. *Front Immunol* 2017;8:1276.

Brewer SM, Brubaker SW, Monack DM. Host inflammasome defense mechanisms and bacterial pathogen evasion strategies. *Curr Opin Immunol* 2019;60:63–70.

Bronner DN, Faber F, Olsen EE et al. Genetic ablation of butyrate utilization attenuates gastrointestinal *Salmonella* disease. *Cell Host Microbe* 2018;23:266–73.e4.

Broz P, Ruby T, Belhocine K et al. Caspase-11 increases susceptibility to *Salmonella* infection in the absence of caspase-1. *Nature* 2012;490:288–91.

Byrne A, Johnson R, Ravenhall M et al. Comparison of *Salmonella enterica* serovars Typhi and Typhimurium reveals typhoidal serovar-specific responses to bile. *Infect Immun* 2018;86:e00490–17.

Carden SE, Walker GT, Honeycutt J et al. Pseudogenization of the secreted effector gene sel confers rapid systemic dissemination of *S. Typhimurium* ST313 within migratory dendritic cells. *Cell Host Microbe* 2017;21:182–94.

Celina J, Hill J, Gunn BM et al. Vi-specific serological correlates of protection for typhoid fever. *J Exp Med* 2021;218:e20201116.

Chen S, Zhang C, Liao C et al. Deletion of invasion protein B in *Salmonella enterica* serovar Typhi and Typhimurium reveals typhoidal serovar-specific responses to bile. *Infect Immun* 2014;82:4553–62.

Chowdhury R, Das S, Ta A et al. Epithelial invasion by *Salmonella Typhi* using STIV–Met interaction. *Cell Microbiol* 2019;21:1–17.

Clements JD, Freytag LC. Parenteral vaccination can be an effective means of inducing protective mucosal responses. *Clin Vaccine Immunol* 2016;23:438–41.

Collier-Hymas LS, Zeng H, Sun J et al. Cutting edge: *Salmonella Avr* effector inhibits the key proinflammatory, anti-apoptotic NF-κB pathway. *J Immunol* 2002;169:2846–50.

Crawford RW, Rosales-Reyes R, Ramirez-Aguilar ML et al. Gallstones play a significant role in *Salmonella* spp. gallbladder colonization and carriage. *Proc Natl Acad Sci USA* 2010;107:4353–8.

Crawford RW, Wangdi T, Spees AM et al. Loss of very-long O-antigen chains optimizes capsule-mediated immune evasion by *Salmonella enterica* serovar Typhi. *mBio* 2013;4:1–8.

Dahora LC, Jin C, Spreng RL et al. IgA and IgG1 specific to Vi polysaccharide of *Salmonella Typhi* correlate with protection status in a typhoid fever controlled human infection model. *Front Immunol* 2019;10:2582.

Daley P, Louie T, Lutz JE et al. Surotomycin versus vancomycin in adults with *Clostridium difficile* infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial. *J Antimicrob Chemother* 2017;72:3462–70.

Darton TC, Blohmke CJ, Giannouloutou E et al. Rapidly Escalating Hepcidin and Associated Serum Iron Starvation Are Features of the Acute Response to Typhoid Infection in Humans. *PLoS Negl Trop Dis* 2015;9:e0004029.
Higgison EE, Simon R, Tennant SM. Animal models for Salmonellosis: applications in vaccine research. Clinical and Vaccine Immunology 2016;23:746–56.

Hiyoshi H, Wangdi T, Lock G et al. Mechanisms to evade the phagocyte respiratory burst arose by convergent evolution in typhoidal Salmonella serovars. Cell Rep 2018;22:1787–97.

Hodge RG, Ridley AJ. Regulating Rho GTPases and their regulators. Nat Rev Mol Cell Biol 2016;17:496–510.

Jayssl W, Gibbs KD, Fricke WF et al. Salmonella activation of STAT3 signaling by SarA effector promotes intracellular replication and production of IL-10. Cell Rep 2018;23:3525–36.

Johansson MEV, Hansson GC. Immunological aspects of intestinal mucus and mucins. Nat Rev Immunol 2016;16:639–49.

John SG, Marshall JM, Baker S et al. Salmonella chronic carriage: epidemiology, diagnosis and gallbladder persistence. Trends Microbiol 2014;22:648–55.

Johnson R, Mylonas E, Frankel G. Typhoidal Salmonella: distinctive virulence factors and pathogenesis. Cell Microbiol 2018;20:1–14.

Juel HB, Thomaides-Brears HB, Darton TC et al. Salmonella Typhi bactericidal antibodies reduce disease severity but do not protect against typhoid fever in a controlled human infection model. Front Immunol 2018;9:1–11.

Kanaiyam R, Mahadeva D. A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Rev Anticancer Ther 2017;18:1249–70.

Keestra-Gounder AM, Tsolis RM, Bäumler AJ. Now you see me, now you don’t: the interaction of Salmonella with innate immune receptors. Nat Rev Microbiol 2015;13:206–16.

Kintz E, Heiss C, Black I et al. Salmonella enterica serovar Typhi lipopolysaccharide O-antigen modification impact on serum resistance and antibody recognition. Infect Immun 2017;85:1–10.

Kortmann J, Brubaker SW, Monack DM. Cutting edge: inflammation in primary human macrophages is dependent on flagellin. J Immunol 2015;195:815–19.

Leclerc J, Dozois CMand Daigle F. Role of the Salmonella enterica serovar Typhi Fur regulator and small RNAs RfrA and RfrB in iron homeostasis and interaction with host cells. Microbiology (Reading) 2013;159:591–602.

Liew ATT, Foo YH, Gao Y et al. Single cell, super-resolution imaging reveals an acid PH-dependent conformational switch in SarB regulates SPI-2. eLife 2019;8:1–26.

Lim D, Soo Kim K, Jeong J-H. The hepcidin-ferroportin axis controls the iron content of Salmonella-containing vacuoles in macrophages. Nat Commun 2018. DOI: 10.1038/s41467-018-04446-8, 2041-1723.

Lovane L, Martinez MJ, Massora S et al. Carriage prevalence of Salmonella enterica serotype Typhi in gallbladders of adult autopsy cases from Mozambique. Journal of Infection in Developing Countries 2016;10:410–12.

Maiti S, Patro S, Purohit S et al. Effective control of Salmonella infections by employing combinations of recombinant antimicrobial human alpha-defensins HBD-1 and HBD-2. Antimicrob Agents Chemother 2014;58:6896–903.

Marcus SL, Brumell JH, Pfeifer CG et al. Salmonella pathogenicity islands: big virulence in small packages. Microbes Infect 2000;2:145–56.

McClelland M, Sanderson KE, Clifton SW et al. Comparison of genome degradation in Paratyphi A and Typhi, human-restricted serovars of Salmonella enterica that cause typhoid. Nat Genet 2004;36:1268–74.
Miao EA, Leaf IA, Treutling PM et al. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat Immunol 2010;11:136–42.

Milligan R, Paul M, Richardson M et al. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev 2018;2018:CD001261.

Müller AA, Dolowschiak T, Sellin ME et al. An NK cell perforin response elicited via IL-18 controls mucosal inflammation kinetics during Salmonella gut infection. PLoS Pathog 2016;12:1–30.

Nair S, Fookes M, Corton C et al. Genetic markers in S. Paratyphi C reveal primary adaptation to pigs. Microorganisms 2020;8:1–10.

Nickerson KP, Senger S, Zhang Y et al. Salmonella Typhi colonization provokes extensive transcriptional changes aimed at evading host mucosal immune defense during early infection of human intestinal tissue. EBiomedicine 2018;31:92–109.

Nuccio S-p, Rüssmann H, Bäumler AJ. The TviA auxiliary protein renders the Salmonella enterica serotype Typhi RcsB regulon responsive to changes in osmolarity. Mol Microbiol 2010;74:175–93.

Näsström E, Jonsson P, Johansson A et al. Diagnostic metabolite biomarkers of chronic typhoid carriage. PLoS Negl Trop Dis 2018;12:1–15.

Ortega AP, Villagra NA, Urrutia IM et al. Lose to win: marT pseudogenization in Salmonella enterica serovar Typhi contributed to the SurV-dependent survival to H2O2, and inside human macrophage-like cells. Infect Genet Evol 2016;45:111–21.

Parquet MdC, Savage KA, Allan DS et al. Novel iron-chelator DIBI inhibits Staphylococcus aureus growth, suppresses experimental MRSA infection in mice and enhances the activities of diverse antibiotics in vitro. Front Microbiol 2018;9:1–11.

Pinna ED, Weill F-X, Peters T. What’s in a name? Species-wide parquet MdC, Savage KA, Allan DS et al. Novel iron-chelator DIBI inhibits Staphylococcus aureus growth, suppresses experimental MRSA infection in mice and enhances the activities of diverse antibiotics in vitro. Front Microbiol 2018;9:1–11.

Prouty AM, Schwesinger WH, Gunn JS. Biofilm formation and interaction with the surfaces of gallstones by Salmonella spp. Infect Immun 2002;70:2640–49.

Puente J, Blanco I, Montoya M et al. Effect of Salmonella Typhi wild type and O-antigen mutants on human natural killer cell activity. Int J Immunopharmacol 2000;22:355–64.

Raffatelli M, Chessa D, Wilson RP et al. The Vi capsule antigen of Salmonella enterica serotype Typhi reduces Toll-like receptor-dependent interleukin-8 expression in the intestinal mucosa. Infect Immun 2005;73:3367–74.

Reens AL, Nagy TA, Detweiler CS. Salmonella enterica requires lipid metabolism genes to replicate in proinflammatory macrophages and mice. Infect Immun 2020;88:1–13.

Riva R, Khoronen TK, Meri S. The outer membrane protease PgtE of Salmonella enterica interferes with the alternative complement pathway by cleaving factors B and H. Front Microbiol 2015;6:1–9.

Ruan HH, Zhang Z, Wang SY et al. Tumor necrosis factor receptor-associated factor 6 (TRAF6) mediates ubiquitination-dependent STAT3 activation upon Salmonella enterica serovar Typhimurium infection. Infect Immun 2017;85:1–13.

Sabbagh SC, Forest CG, Lepage C et al. So similar, yet so different: uncovering distinctive features in the genomes of Salmonella enterica serovars Typhimurium and Typhi. FEMS Microbiol Lett 2010;305:1–13.

Salerno-Goncalves R, Galen JE, Levine MM et al. Manipulation of Salmonella Typhi Gene expression impacts innate cell responses in the human intestinal mucosa. Front Immunol 2018;9:1–15.

Salerno-Goncalves R, Kayastha D, Fasano A et al. Crosstalk between leukocytes triggers differential immune responses against Salmonella enterica serovars Typhi and Paratyphi. PLoS Negl Trop Dis 2019;13:e0007650.

Smykannu G, Vijayababu P, Antonyraj CB et al. In silico characterization of B cell and T Cell epitopes for subunit vaccine design of Salmonella Typhi PgtE: a molecular dynamics simulation approach. J Comput Biol 2018;26:105–16.

Schreiber F, Kay S, Frankel G et al. The Hd, Hj, and Hz66 flagella variants of Salmonella enterica serovar Typhi modify host responses and cellular interactions. Sci Rep 2015;5:1–10.

Simuyandi M, Kapulu M. Anti-microbial peptide gene expression during oral vaccination: analysis of a randomized controlled trial. Clin Exp Immunol 2016;186:205–13.

Spano S, Galán JE. A Rab32-dependent pathway contributes to Salmonella Typhi host restriction. Science 2012;338:960–63.

Stanaway JD, Reiner RC, Blacker BF et al. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the global burden of disease study 2017. Lancet Infect Dis 2019;19:369–81.

TheeYa N, Ta A, Das S et al. An inducible and secreted eukaryotic-like serine/threonine Kinase of Salmonella enterica serovar Typhi promotes intracellular survival and pathogenesis. Infect Immun 2015;83:522–33.

Toapanta FR, Bernal PJ, Frensay S et al. Oral Challenge with Wild-Type Salmonella Typhi Induces Distinct Changes in B Cell Subsets in Individuals Who Develop Typhoid Disease. PLoS Negl Trop Dis 2016;10:e0004766.

UniProt. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res 2019;47:D506–15.

Valenzuela LM, Hidalgo AA, Rodríguez L et al. Pseudogenization of SopA and SopE2 is functionally linked and contributes to virulence of Salmonella enterica Serovar Typhi. Infect Genet Evol 2015;33:131–42.

Vazquez-Torres A, Jones-Carson J, Bäumler A et al. Extraintestinal dissemination of Salmonella by CD18-expressing phagocytes. Nature 1999;401:804–8.

Velásquez JC, Hidalgo AA, Villagrá N et al. SPI-9 of Salmonella enterica serovar Typhi is constituted by an operon positively regulated by RpoS and contributes to adherence to epithelial cells in culture. Microbiology 2016;162:1367–78.

Vila J, Moreno-Mora1es J, Ballesté-Delpierre C. Current landscape in the discovery of novel antibacterial agents. Clin Microbiol Infect 2020;26:596–603.

Waddington CS, Darton TC, Woodward WE et al. Advancing the management and control of typhoid fever: a review of the historical role of human challenge studies. J Infect 2014;68:405–18.

Walawalkar YD, Vaidya Y, Nayak V. Response of Salmonella Typhi to bile-generated oxidative stress: implication of quorum sensing and persister cell populations. Pathog Dis 2016;74:1–7.

Wangdi T, Lee CY, Spees AM et al. SufC may promote the survival of Salmonella enterica serovar Typhi in macrophages. Microb Pathog 2015;85:40–43.
Wilson RP, Raffatellu M, Chessa D et al. The Vi-capsule prevents toll-like receptor 4 recognition of Salmonella. Cell Microbiol 2008;10:876–90.

Wilson RP, Winter SE, Spees AM et al. The Vi capsular polysaccharide prevents complement receptor 3-mediated clearance of Salmonella enterica serotype Typhi. Infect Immun 2011;79:830–37.

Winter SE, Winter MG, Atluri V et al. The flagellar regulator TviA reduces pyroptosis by Salmonella enterica serovar Typhi. Infect Immun 2015;83:1546–55.

Winter SE, Winter MG, Poon V et al. Salmonella enterica serovar Typhi conceals the invasion-associated type three secretion system from the innate immune system by gene regulation. PLoS Pathog 2014;10:e1004207.

World Health Organization. Antigenic Formulae of the Salmonella Serovars. 2007. https://www.pasteur.fr/sites/default/files/ven0.pdf.

Xu J, Preciado-Llanes L, Aulicino A et al. Single-cell and time-resolved profiling of intracellular Salmonella metabolism in primary human cells. Anal Chem 2019;91:7729–37.

Yang J, Zhang E, Liu F et al. Flagellins of Salmonella Typhi and nonpathogenic Escherichia coli are differentially recognized through the NLRC4 pathway in macrophages. J Innate Immun 2014;6:47–57.

Yin J, Cheng Z, Wu Y et al. Characterization and protective efficacy of a Salmonella pathogenicity island 2 (SPI2) mutant of Salmonella Paratyphi A. Microb Pathog 2020;137:103795.

Yue M, Han X, De Masi L et al. Allelic variation contributes to bacterial host specificity. Nat Commun 2017;8:15229.

Zhang Y, Brady A, Jones CC et al. Compositional and functional differences in the human gut microbiome correlate with clinical outcome following infection with wild-type Salmonella enterica serovar Typhi. mBio 2018;9:1–14.